Golomb Beatrice A, Allison Matthew, Koperski Sabrina, Koslik Hayley J, Devaraj Sridevi, Ritchie Janis B
Departments of Medicine and of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093, U.S.A.
Neural Comput. 2014 Nov;26(11):2594-651. doi: 10.1162/NECO_a_00659. Epub 2014 Aug 22.
We sought to assess whether coenzyme Q10 (CoQ10) benefits the chronic multisymptom problems that affect one-quarter to one-third of 1990-1 Gulf War veterans, using a randomized, double-blind, placebo-controlled study. Participants were 46 veterans meeting Kansas and Centers for Disease Control criteria for Gulf War illness. Intervention was PharmaNord (Denmark) CoQ10 100 mg per day (Q100), 300 mg per day (Q300), or an identical-appearing placebo for 3.5 ± 0.5 months. General self-rated health (GSRH), the primary outcome, differed across randomization arms at baseline, and sex significantly predicted GSRH change, compelling adjustment for baseline GSRH and prompting sex-stratified analysis. GSRH showed no significant benefit in the combined-sex sample. Among males (85% of participants), Q100 significantly benefited GSRH versus placebo and versus Q300, providing emphasis on Q100. Physical function (summary performance score, SPS) improved on Q100 versus placebo. A rise in CoQ10 approached significance as a predictor of improvement in GSRH and significantly predicted SPS improvement. Among 20 symptoms each present in half or more of the enrolled veterans, direction-of-difference on Q100 versus placebo was favorable for all except sleep problems; sign test 19:1, p=0.00004) with several symptoms individually significant. Significance for these symptoms despite the small sample underscores large effect sizes, and an apparent relation of key outcomes to CoQ10 change increases prospects for causality. In conclusion, Q100 conferred benefit to physical function and symptoms in veterans with Gulf War illness. Examination in a larger sample is warranted, and findings from this study can inform the conduct of a larger trial.
我们试图通过一项随机、双盲、安慰剂对照研究，评估辅酶Q10（CoQ10）是否对影响1990 - 1年海湾战争退伍军人四分之一至三分之一的慢性多症状问题有益。参与者为46名符合堪萨斯州和疾病控制中心海湾战争疾病标准的退伍军人。干预措施为丹麦法尔诺德公司生产的每日100毫克CoQ10（Q100）、每日300毫克CoQ10（Q300）或外观相同的安慰剂，为期3.5±0.5个月。主要结局指标一般自我评定健康状况（GSRH）在基线时各随机分组之间存在差异，性别显著预测了GSRH的变化，因此有必要对基线GSRH进行调整并进行性别分层分析。在合并性别的样本中，GSRH未显示出显著益处。在男性（占参与者的85%）中，与安慰剂和Q300相比，QlOO对GSRH有显著益处，突出了Q100的作用。与安慰剂相比，Q100组的身体功能（综合表现评分，SPS）有所改善。CoQ10水平升高作为GSRH改善的预测指标接近显著水平，并显著预测了SPS的改善。在半数或更多登记退伍军人中出现过的20种症状中，与安慰剂相比，Q100组在除睡眠问题外的所有症状上差异方向均有利；符号检验为19:1，p = 0.00004），有几种症状单独具有显著性。尽管样本量较小，但这些症状的显著性突出了效应量较大，并且关键结局与CoQ10变化的明显关系增加了因果关系的可能性。总之Q100对患有海湾战争疾病的退伍军人的身体功能和症状有益。有必要在更大样本中进行检验，本研究结果可为开展更大规模试验提供参考。
